BR0208860A - Use of a cationic dextran derivative, method for protecting an individual against dose-limiting organ damage, and method for protecting an individual against renal damage - Google Patents

Use of a cationic dextran derivative, method for protecting an individual against dose-limiting organ damage, and method for protecting an individual against renal damage

Info

Publication number
BR0208860A
BR0208860A BR0208860-6A BR0208860A BR0208860A BR 0208860 A BR0208860 A BR 0208860A BR 0208860 A BR0208860 A BR 0208860A BR 0208860 A BR0208860 A BR 0208860A
Authority
BR
Brazil
Prior art keywords
protecting
damage
individual against
dose
individual
Prior art date
Application number
BR0208860-6A
Other languages
Portuguese (pt)
Inventor
Anders Holmberg
Jukka Hiltunen
Giovanni Paganelli
Marta Cremones
Original Assignee
Map Medical Technologies Oy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Map Medical Technologies Oy filed Critical Map Medical Technologies Oy
Publication of BR0208860A publication Critical patent/BR0208860A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/721—Dextrans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
    • C08B37/0021—Dextran, i.e. (alpha-1,4)-D-glucan; Derivatives thereof, e.g. Sephadex, i.e. crosslinked dextran

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Materials Engineering (AREA)
  • Polymers & Plastics (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

"USO DE UM DERIVADO DE DEXTRANO CATIÈNICO, MéTODO PARA A PROTEçãO DE UM INDIVìDUO CONTRA O DANO EM óRGãOS COM LIMITAçãO DE DOSE, E, MéTODO PARA A PROTEçãO DE UM INDIVìDUO CONTRA DANO RENAL". A presente invenção refere-se ao uso de derivados de dextrano catiónicos providos com substituintes tendo grupos laterais positivamente carregados como agentes de proteção para órgão com limitação de dosagem no tratamento sistêmico de doenças, incluindo câncer. Os derivados de dextrano catiónicos são agentes nefroprotetores particularmente úteis para um indivíduo, que esteja recebendo tratamento sistêmico com produtos farmacêuticos citostáticos, radionuclídeos ou compostos que portam radionuclídeos contra dano renal. Os derivados de dextrano catiónicos não apenas protegem os órgãos com limitação de dose, mas são melhor tolerados a apresentam menores efeitos colaterais do que os agentes de proteção convencionalmente usados."USE OF A CATIENIC DEXTRAN DERIVATIVE, A METHOD FOR PROTECTION OF AN INDIVIDUAL FROM DAMAGE LIMITATED DAMAGES, AND A METHOD FOR PROTECTION OF AN INDIVIDUAL AGAINST RENAL DAMAGE". The present invention relates to the use of cationic dextran derivatives provided with substituents having positively charged side groups as dose-limiting organ protection agents in the systemic treatment of diseases, including cancer. Cationic dextran derivatives are particularly useful nephroprotective agents for an individual receiving systemic treatment with cytostatic pharmaceuticals, radionuclides or radionuclide-bearing compounds against renal damage. Cationic dextran derivatives not only protect dose-limiting organs, but are better tolerated to have fewer side effects than conventional protective agents.

BR0208860-6A 2001-04-11 2002-04-11 Use of a cationic dextran derivative, method for protecting an individual against dose-limiting organ damage, and method for protecting an individual against renal damage BR0208860A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FI20010764A FI20010764A0 (en) 2001-04-11 2001-04-11 Cationic dextran derivatives for use in renal protection
PCT/FI2002/000305 WO2002083154A1 (en) 2001-04-11 2002-04-11 Use of cationic dextran derivatives for protecting dose-limiting organs

Publications (1)

Publication Number Publication Date
BR0208860A true BR0208860A (en) 2004-10-19

Family

ID=8560975

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0208860-6A BR0208860A (en) 2001-04-11 2002-04-11 Use of a cationic dextran derivative, method for protecting an individual against dose-limiting organ damage, and method for protecting an individual against renal damage

Country Status (13)

Country Link
EP (1) EP1383517A1 (en)
JP (1) JP2004525181A (en)
KR (1) KR20040018350A (en)
BR (1) BR0208860A (en)
CA (1) CA2443052A1 (en)
EE (1) EE200300502A (en)
FI (1) FI20010764A0 (en)
HU (1) HUP0401386A3 (en)
IL (1) IL158153A0 (en)
NO (1) NO20034561L (en)
PL (1) PL363024A1 (en)
RU (1) RU2003132683A (en)
WO (1) WO2002083154A1 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010102065A1 (en) 2009-03-05 2010-09-10 Bend Research, Inc. Pharmaceutical compositions of dextran polymer derivatives
ES2873502T3 (en) 2009-03-27 2021-11-03 Bend Res Inc Spray drying process
EP2611529B1 (en) 2010-09-03 2019-01-23 Bend Research, Inc. Spray-drying method
WO2012031133A2 (en) 2010-09-03 2012-03-08 Bench Research, Inc. Spray-drying apparatus and methods of using the same
US8815294B2 (en) 2010-09-03 2014-08-26 Bend Research, Inc. Pharmaceutical compositions of dextran polymer derivatives and a carrier material
WO2012040502A1 (en) 2010-09-24 2012-03-29 Bend Research, Inc. High-temperature spray drying process and apparatus
US9084727B2 (en) 2011-05-10 2015-07-21 Bend Research, Inc. Methods and compositions for maintaining active agents in intra-articular spaces
DE102014016901B4 (en) * 2014-09-17 2021-08-12 Friedrich-Schiller-Universität Jena Process for the production of new dextran derivatives as active ingredient carrier systems and their use
CA3044891A1 (en) * 2016-12-01 2018-06-07 Norbert Gretz Means and methods for visualization of tissue structures
BR112022011800A2 (en) * 2019-12-14 2022-08-30 Chaudhary Manu POLYBASIC DRUG FORMULATIONS TO REDUCE MULTIPLE ORGAN TOXICITY

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3414491A1 (en) * 1984-04-17 1985-10-24 Hans Dr. 8202 Bad Aibling Dietl L-Amino acid mixtures for parenteral and oral use for kidney disorders
US5290538A (en) * 1988-12-22 1994-03-01 Skrezek Christian Nephro protective infusion solutions
SE9803482D0 (en) * 1998-10-13 1998-10-13 Anders Holmberg Ion exchange tumor targeting (IETT)
EP1196154B1 (en) * 1999-07-16 2006-09-13 Mallinckrodt, Inc. Inhibition of renal uptake of radiomolecules with a combination of lysine and arginine

Also Published As

Publication number Publication date
PL363024A1 (en) 2004-11-15
EP1383517A1 (en) 2004-01-28
HUP0401386A3 (en) 2005-06-28
IL158153A0 (en) 2004-03-28
JP2004525181A (en) 2004-08-19
NO20034561D0 (en) 2003-10-10
HUP0401386A2 (en) 2004-12-28
KR20040018350A (en) 2004-03-03
RU2003132683A (en) 2005-04-10
EE200300502A (en) 2003-12-15
NO20034561L (en) 2003-12-09
FI20010764A0 (en) 2001-04-11
WO2002083154A1 (en) 2002-10-24
CA2443052A1 (en) 2002-10-24

Similar Documents

Publication Publication Date Title
ATE162706T1 (en) AGENTS FOR ARTIFICIAL SUN TANNING AND FOR PROTECTING THE SKIN AGAINST UV RAYS
DK0752842T3 (en) Preparations with improved stability for artificial tanning
BR0010716A (en) Phenyl compounds substituted with immunosuppressive activity and pharmaceutical compositions
ATE229506T1 (en) 1-(2-OXO-ACETYL)-PIPERIDINE-2-CARBONIC ACID DERIVATIVES AS SENSITIZERS FOR MULTI-DRUG-RESISTANT CANCER CELLS
BR0312957A (en) A compound or a pharmaceutically acceptable salt thereof, use thereof, pharmaceutical composition, and method for producing an inhibitory effect of 11betahsd1 on a warm-blooded animal such as man in need of such treatment.
BR0015911A (en) Benzoimidazole derivatives useful as antiproliferative agents
CL2010000606A1 (en) Use of erythropoietin derivatives in the preparation of a useful medicine to protect, maintain, improve or recover the viability of cells that respond to erythropoietin under abnormal conditions that affect the associated cells, tissues or organs; Erythropoietin derivatives and composition comprising them (divisional of application 3188-2001).
BRPI0312464B8 (en) tyrosine kinase inhibitor compounds, pharmaceutical compositions comprising them, processes for manufacturing and uses thereof
TR199903053T2 (en) Benzimidazole trevleri.
FI953748A (en) Compounds with both potent calcium antagonist and antioxidant activity and their use as cell protective agents
BR9912098A (en) Thiobenzimidazole derivative, pharmaceutical composition, and, preventive and / or therapeutic agent
MX9703621A (en) Novel amino acid derivatives with improved multi-drug resistance activity.
BRPI0513513A (en) compound or a pharmaceutically acceptable salt thereof, process for preparing it, pharmaceutical composition, use of a compound or a pharmaceutically acceptable salt thereof, and methods for producing an eg5 inhibitory effect and an anticancer effect on a warm-blooded animal , and to treat carcinomas in a warm-blooded animal
TR199901904T2 (en) 3-pyridyl enantiomers and their use as analgesics.
BR0318278A (en) aminocyclohexyl ether compounds and uses thereof
BR9306410A (en) Derivatives of 3-arylpyrazoles processes for the preparation of these derivatives fungicidal compositions and method for protecting plants against fungal diseases
BR0208860A (en) Use of a cationic dextran derivative, method for protecting an individual against dose-limiting organ damage, and method for protecting an individual against renal damage
ATE287267T1 (en) COMBINATION THERAPIES WITH VASCULAR DAMAGE ACTIVITY
ATE439134T1 (en) MEDICINE FOR PROTECTION IN RADIOTHERAPY
BR0011225A (en) Agent to treat dry eyes, its method and use
BR9909087A (en) Formulations for protection of peg-alpha interferon conjugates
BR0008297A (en) Use of 4,6-o- (benzylidene-d1) -d-glucopyranose, 4,6-o-benzylidene-1-glucopyranose, and / or 4,6-o- (benzylidene-d1) -l-glucopyranose, or an acceptable pharmaceutical salt thereof, derived from benzaldehyde pharmaceutical composition, and process for the manufacture thereof
BR9904541A (en) Cosmetic composition for topical use, use of the composition and use of at least one derivative of cinnamic acid and / or at least one derivative of salicylic acid
BR0311491A (en) Compound, Pharmaceutical Composition, Use of a Compound, and, Therapeutic Method to Treat Cancer in a Mammal
BR0011880A (en) Method for the treatment of co-morbid conditions associated with obesity, compound, product, use of a compound, and pharmaceutical composition

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]